ST Renfu: The application for listing approval of the subsidiary company's drug, Methylphenidate Hydrochloride Extended-Release Capsules, has been accepted

2026-04-10 08:56:04

People’s Financial News, April 8 — ST Renfu (6000790192837465657483920, in an announcement made on April 8, said that its controlling subsidiary, Yichang Renfu, has recently received an acceptance notice from the National Medical Products Administration for the drug registration and marketing approval application of Ritalin hydrochloride extended-release capsules (methylphenidate hydrochloride extended-release capsules). The Ritalin hydrochloride extended-release capsules are mainly used to treat attention deficit hyperactivity disorder (ADHD) in children aged 6 and above.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.